Cost-effectiveness of eptifibatide in patients undergoing planned coronary stenting: Results from the ESPRIT trial

被引：0
|
作者：
Cohen, DJ
Cosgrove, RS
Berezin, RH
O'Shea, J
Kitt, MM
Gilchrist, I
Mark, DB
Tcheng, JE
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[2] Harvard Clin Res Inst, Boston, MA USA
[3] Duke Clin Res Inst, Durham, NC USA
[4] Cor Therapeut, San Francisco, CA USA
[5] Penn State Univ, Coll Med, College Stn, PA USA
来源：
CIRCULATION | 2001年 / 104卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1841
引用
收藏
页码：386 / 387
页数：2
相关论文
共 50 条
  • [31] Cost-effectiveness of distal embolic protection for patients undergoing percutaneous - Intervention of saphenous vein bypass grafts: Results from the SAFER trial
    Cohen, DJ
    Murphy, SA
    Baim, DS
    Lavelle, TA
    Berezin, RH
    Cutlip, DE
    Ho, KKL
    Kuntz, RE
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (09) : 1801 - 1808
  • [32] Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: Acute coronary syndromes and elective stenting
    Granada J.F.
    Kleiman N.S.
    American Journal of Cardiovascular Drugs, 2004, 4 (1) : 31 - 41
  • [33] The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial
    B. Jönsson
    J. R. Cook
    T. R. Pedersen
    Diabetologia, 1999, 42 : 1293 - 1301
  • [34] The cost-effectiveness of lipid lowering in patients with diabetes:: results from the 4S trial
    Jönsson, B
    Cook, JR
    Pedersen, TR
    DIABETOLOGIA, 1999, 42 (11) : 1293 - 1301
  • [35] REHABILITATION IN RESURFACING HIP ARTHROPLASTY PATIENTS: PRELIMINARY COST-EFFECTIVENESS RESULTS FROM A CLINICAL TRIAL
    Fusco, F.
    Campbell, H.
    Newman, M.
    Barker, K.
    VALUE IN HEALTH, 2014, 17 (07) : A381 - A382
  • [36] Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes The ODYSSEY OUTCOMES Trial
    Bhatt, Deepak L.
    Briggs, Andrew H.
    Reed, Shelby D.
    Annemans, Lieven
    Szarek, Michael
    Bittner, Vera A.
    Diaz, Rafael
    Goodman, Shaun G.
    Harrington, Robert A.
    Higuchi, Keiko
    Joulain, Florence
    Jukema, J. Wouter
    Li, Qian H.
    Mahaffey, Kenneth W.
    Sanchez, Robert J.
    Roe, Matthew T.
    Lopes, Renato D.
    White, Harvey D.
    Zeiher, Andreas M.
    Schwartz, Gregory G.
    Steg, Ph. Gabriel
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (18) : 2297 - 2308
  • [37] Cost effectiveness of eptifibatide in acute coronary syndromes - An economic analysis of Western European patients enrolled in the PURSUIT trial
    Brown, RE
    Henderson, RA
    Koster, D
    Hutton, J
    Simoons, ML
    EUROPEAN HEART JOURNAL, 2002, 23 (01) : 50 - 58
  • [38] Cost-effectiveness of prasugrel versus clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention
    Spartalis, Michael
    Tzatzaki, Eleni
    Nikiteas, Nikolaos I.
    Spartalis, Eleftherios
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 251 : 32 - 32
  • [39] Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis
    Lala, A.
    Berger, J. S.
    Sharma, G.
    Hochman, J. S.
    Braithwaite, R. Scott
    Ladapo, J. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 (01) : 81 - 91
  • [40] Cost and cost-effectiveness of intravenous enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention: Results from the STEEPLE trial
    Zhao, Liping
    Ewen, Edward
    Zhang, Zefeng
    Bowen, James
    Jurkovitz, Claudine
    Leguet, Prisca
    Kolm, Paul
    Weintraub, William S.
    CIRCULATION, 2006, 114 (18) : 827 - 827
12345